Results
1
-
10
of
93
<
1
2
3
...
9
10
>
Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in ?-Thalassaemia Major Patients: An Italian Perspective.
,
Clinical Drug Investigation
[DOI: 10.1007/s40261-017-0496-1]
Iron chelator-induced apoptosis via the ER stress pathway in gastric cancer cells.
,
Tumor Biology
[DOI: 10.1007/s13277-016-4878-4]
Longitudinal changes of endocrine and bone disease in adults with ?-thalassemia major receiving different iron chelators over 5 years.
,
Annals of Hematology
[DOI: 10.1007/s00277-016-2633-y]
Nephrolithiasis in patients exposed to deferasirox and desferioxamine: probably an age-linked event with different effects on some renal parameters.
,
Annals of Hematology
[DOI: 10.1007/s00277-013-1833-y]
Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective.
,
Clinical Drug Investigation
[DOI: 10.1007/s40261-012-0008-2]
Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients.
,
Annals of Hematology
[DOI: 10.1007/s00277-012-1480-8]
Challenges of adherence and persistence with iron chelation therapy.
,
International Journal of Hematology
[DOI: 10.1007/s12185-011-0927-3]
Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration.
,
Journal of Neural Transmission
[DOI: 10.1007/s00702-010-0531-3]
The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study.
,
Journal of Cardiovascular Magnetic Resonance
[DOI: 10.1186/1532-429X-11-20]
Iron chelation therapy in the myelodysplastic syndromes and aplastic anemia: a review of experience in South Korea.
,
International Journal of Hematology
[DOI: 10.1007/s12185-008-0117-0]
<
1
2
3
...
9
10
>